A recent report highlighted the potential therapeutic targets in modulating microglial functions for Alzheimer’s disease (AD) as NLRP3 inflammasome activation (VRAC, P2X7, NLRP3), complement production and signalling (C1, C1q, C3, CR1, Factor B, Factor D, and Properdin), and TREM2/DAP12 signalling (TREM2, SHIP-1, PLCγ2, and Apolipoprotein E) (Nizami et al., 2019). This evidence concerns the gene LIF and Alzheimer disease.